|
Apr 30
|
Curious about Neurocrine (NBIX) Q1 Performance? Explore Wall Street Estimates for Key Metrics
|
|
Apr 24
|
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
|
|
Apr 24
|
Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
|
|
Apr 24
|
3 Red-Hot Biotech Rockets Blasting Off in 2024
|
|
Apr 23
|
Does Neurocrine, The No. 1 Biotech Stock, Have The Next Ketamine On Its Hands?
|
|
Apr 23
|
Neurocrine scores surprise win with depression drug
|
|
Apr 23
|
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
|
|
Apr 22
|
10 Best Performing Biotech ETFs in 2024
|
|
Apr 16
|
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
|
|
Apr 10
|
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results
|
|
Apr 9
|
11 Best Biotech ETFs To Buy
|
|
Apr 3
|
Is Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Recent Performance Tethered To Its Attractive Financial Prospects?
|
|
Apr 3
|
Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
|
|
Mar 28
|
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
|
|
Mar 23
|
S&P 500 Giants Lead Five Stocks Near Buy Points With Fed's Powell A Tailwind
|
|
Mar 21
|
Dow Jones Futures: Market Fades On Sour Apple, But These 11 Stocks Flash Buy Signals; FedEx Soars Late
|
|
Mar 16
|
AI Plays HubSpot, Arista Networks Lead Five Stocks Near Buy Points In Classic Base
|
|
Mar 16
|
Neurocrine Biosciences Inc's Chief Regulatory Officer Ingrid Delaet Sells 3,000 Shares
|
|
Mar 16
|
Director Richard Pops Sells 23,200 Shares of Neurocrine Biosciences Inc (NBIX)
|
|
Mar 15
|
Neurocrine Biosciences Is Pioneering Therapies for Neurological Disorders
|